Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Pre-Registration for Community-Acquired Bacterial Pneumonia. According to GlobalData, Pre-Registration drugs for Community-Acquired Bacterial Pneumonia have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Ceftobiprole medocaril’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ceftobiprole medocaril overview

Ceftobiprole medocaril (Zeftera/Zevtera/Mabelio) a broad-spectrum cephalosporin antibiotic. It is formulated as powder for solution for intravenous administration. Zevtera is indicated for the treatment of the following infections in adults : Hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), Community-acquired pneumonia (CAP). Zeftera is indicated for the treatment of the following infections when caused by complicated skin and skin structure infections (cSSSI), including non-limb threatening diabetic foot infections without concomitant osteomyelitis caused by: Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus aureus (including methicillin-resistant isolates), and Streptococcus pyogenes.

It is also under development for the treatment of bacterial endocarditis, skin and skin structure infections (SSSI) caused by bacteria, sepsis and Staphylococcus aureus bacteremia. It was under development for the treatment of diabetic foot infection (DFI), methicillin-resistant Staphylococcus Aureus (MRSA) infections, hospital acquired pneumonia (HAP), community acquired pneumonia and pneumonia.

Basilea Pharmaceutica overview

Basilea Pharmaceutica (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company products are for increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial infections, and fungal infections. Basilea also conducts research in the areas of anti-infectives, cancer, and bacterial or fungal strains. It discovers drugs with the help of various technologies such as genomics, assay development, cell biology and others. The company also operates in France, the UK, China, Germany, Spain, Switzerland, Italy, and Denmark. Basilea is headquartered in Basel, Zurich, Switzerland.

For a complete picture of Ceftobiprole medocaril’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 17 November 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.